Certara (NASDAQ:CERT) Shares Gap Up - Still a Buy?

Certara, Inc. (NASDAQ:CERT - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $11.00, but opened at $11.45. Certara shares last traded at $10.96, with a volume of 153,781 shares trading hands.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on CERT shares. William Blair reaffirmed a "market perform" rating on shares of Certara in a report on Thursday, February 27th. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. Robert W. Baird increased their price target on shares of Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, April 11th. TD Cowen assumed coverage on shares of Certara in a report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective on the stock. Finally, Stephens restated an "overweight" rating and set a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $15.67.

Certara Price Performance

The company has a 50-day moving average of $11.95 and a 200-day moving average of $11.80. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -59.75, a P/E/G ratio of 9.29 and a beta of 1.44. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Certara (NASDAQ:CERT - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. The company had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the company earned $0.10 EPS. As a group, equities research analysts expect that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc boosted its holdings in shares of Certara by 218.8% during the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock worth $27,000 after purchasing an additional 1,866 shares during the last quarter. Venturi Wealth Management LLC lifted its position in Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after buying an additional 2,509 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Certara during the first quarter worth about $31,000. Wells Fargo & Company MN lifted its position in Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after buying an additional 1,047 shares during the period. Finally, AlphaQuest LLC acquired a new stake in Certara in the 1st quarter worth about $39,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.